stem cell therapy

People with multiple sclerosis (MS) tend to experience a short-term reduction in disability and brain lesion volume after receiving stem cell therapy, according to a meta-analysis of nine studies detailing randomized clinical trials. After six and 12 months, however, the researchers found no differences in disability between patients…

The National Institute of Neurological Disorders and Stroke has awarded a $2.9 million, five-year grant to a research project that aims to advance a new technology that could improve stem cell therapies for multiple sclerosis (MS) and other neurological disorders. “The work we plan to undertake has significant implications…

People with multiple sclerosis (MS) have higher amounts of mitochondrial DNA in their spinal fluid, which surrounds the brain and spinal cord, than do their healthy counterparts, a small study found. Mitochondria are small cellular organelles that produce most of the energy needed to power cells. These cell powerhouses…

A novel therapy in which neural stem cells are injected into the brain was well tolerated by 15 people with secondary progressive multiple sclerosis (SPMS) in a pilot clinical trial. Participants’ disability levels and cognition, as well as markers of inflammation and nerve damage, all remained stable for up…

Nearly 80% of adults with highly active relapsing-remitting multiple sclerosis (RRMS) were free of relapses or confirmed disability worsening two years after receiving stem cell transplant, according to a real-world study in Denmark. Moreover, more than two-thirds (69%) of these RRMS patients achieved a clinical outcome called NEDA-3, or…

People with multiple sclerosis (MS) who have never received treatment with a disease-modifying therapy tend to have better long-term outcomes after stem cell transplant, according to a recent report from a center in Mexico. The findings suggest that stem cell therapy may be most beneficial when given…

Use of the cell therapy MSC-NP failed to show a significant effect on overall disability scores among people with progressive forms of multiple sclerosis (MS), according to data from a Phase 2 clinical trial. Results, however, indicated that MSC-NP improved walking ability for people with more advanced disease —…

MSC-NP, a form of stem cell therapy that’s currently in early clinical trials for multiple sclerosis (MS), can reduce the inflammatory activity of brain immune cells called microglia, according to a new study. The therapy is known to reduce disease severity and improve myelin regeneration in animal models of…

NurOwn, a stem cell therapy being developed by BrainStorm Cell Therapeutics, showed a good safety profile among people with progressive forms of multiple sclerosis (MS) in an open-label Phase 2 clinical trial, according to new data. The data show the experimental therapy also was associated with promising effects on…

Lesser or stable disability over two years was evident in most progressive multiple sclerosis (MS) patients given a stem cell treatment in a small Phase 1 clinical trial, supporting a larger study now underway, researchers report. These results suggest that a treatment using mesenchymal stem…

Transplanting mesenchymal stem cells (MSCs) is safe and can delay disease progression in people with active, progressive multiple sclerosis (MS), according to results from a single-center clinical trial conducted in Israel. Six months after the transplant, a considerable proportion of patients showed no signs of disease activity, compared to…

Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum topic “Has anyone had the stem cell procedure?” from Jan. 11. You’ve no doubt heard…

Medical tourism is a term describing when people seek medical care by traveling from home countries to somewhere else. It’s an area of commerce that has existed for centuries, as people in ancient Greece once traveled to far away islands to visit healing gods. Medical tourism continues today, and…

I started out in my professional life as a journalist. This only lasted about eight years and feels like a lifetime ago — which it was. Though I was not a news hound, I learned to smell a story. Last week’s column, “A Tale of Two Halves,” juxtaposed bad MS…

Americans who want to treat their MS with a stem cell transplant have a tough road to follow. They’re forced to travel to Russia, Mexico, or somewhere else out of the country and to spend a lot of money to avoid the U.S. Food and Drug Administration’s stem cell…

Editor’s note: Tamara Sellman continues her series on the “MS alphabet” with this column referencing terms starting with the letter “S.” Last in a series of five. Symptoms of MS Spasticity This refers to the muscle stiffness and issues with muscular control and abnormal muscle tone that…

Advancells says its stem cell-based therapy completely reversed multiple sclerosis (MS) in an Indian pilot trial with only one MS patient. The patient, Rahul Gupta, was diagnosed with MS seven years ago and has since suffered multiple relapses. His disease was progressing fast and he was quickly losing his ability…

I regularly see comments on various social media sites from MS patients who have traveled, or who plan to travel, outside the U.S. to be treated with stem cells. Some of these patients have reported excellent results and a reversal of symptoms. Others have died. Many MS patients…

In case you missed them, here are some news stories that appeared in MS News Today that caught my eye over the past week. Experts Call for Tighter Regulation of Stem Cell Therapies in Use at Clinics Worldwide I read a lot of comments on various social…

A number of important discoveries, therapeutic developments, and events related to multiple sclerosis (MS) were reported daily by Multiple Sclerosis News Today throughout 2016. Now that the year is over, it is time to briefly review the articles that appealed most to our readers. Here are the top 10 most-read articles of 2016, with…

News that the U.S. Food and Drug Administration (FDA) is to hold a public hearing next month to consider greater oversight of stem cell clinics operating in the country is as welcome as it is late. I say “late” because, while the regulators have been twiddling their fingers,…

Karen Staman and I met a while back through a National Institute of Health and Duke University research collaborative effort.  She is a scientific writer by trade, which means she sits through lots of conversation and puts everyone else’s thoughts into cohesive sentences that can then be published, and…

News that scientists in the U.S. are working to find a new pre-HSCT treatment to carry out stem cell transplants without the need for chemotherapy, as published in Multiple Sclerosis News Today, leaves me with mixed feelings. While such a development could potentially be great news and an…

Can we all agree that research studies are important and they are necessary to prove whether a concept works or it doesn’t? Even from the biggest failures, we can learn more. We can also all agree that research has to be done via properly conducted studies to be accepted as…

Allegations that false claims regarding treatment were made to potential patients, as well as one of its proponents having at least one fake degree, are being leveled against a stem cell clinic that was operating in India two years ago. The clinic was not offering HSCT, but rather a form of combination…

Stem cell treatment of MS, which came under the spotlight at last week’s 16th Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) when Dr. Mark Freedman discussed the procedure, is an exciting area within the development of therapies. Dr. Freedman, professor of medicine (neurology) at the…

Dr. Andrew Goodman of the University of Rochester discussed the latest research and perspectives on stem cell strategies for people with multiple sclerosis (MS), saying in a presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016 that such therapies, while promising, are not yet ready for widespread clinical use. New therapies…

Geoff Flynn, 42, was diagnosed with multiple sclerosis (MS) two and a half years ago. As unsettling as that diagnosis was, more troubling — both then and now — were the five long years of struggle it took for him to get a proper evaluation as to the cause of his neurological…

The U.S. Food and Drug Administration (FDA) will hold a one-day public hearing on four recent draft guidelines regarding the regulation of human cells, tissues, or cellular or tissue-based products (HCT/Ps). Critics of the proposed regulations warn that they curtail the medical use of autologous cell therapy and biologics, and their future potential…